文献速递心外重症与机械循环支持先天性心脏病外科

Berlin Heart EXCOR 上市后监测研究:ACTION 注册报告

Berlin Heart EXCOR and ACTION post-approval surveillance study report.
PubMed 文献 · J Heart Lung Transplant · 2021-01-19

该研究基于 ACTION 注册中 2018–2020 年北美 72 例 EXCOR 植入患者,与历史 BHS 组 320 例比较。PSS 组更年幼、体重/体表面积更小、先心病更多、双心室辅助更少,92% 以比伐卢定抗凝。180 天成功率为 86% vs 76%,卒中减少 44%,泵更换减少 40%,其他不良事件包括大出血均减少。

要点

  • EXCOR 儿童 VAD 上市后监测显示 180 天成功率达 86%,高于历史组的 76%。
  • PSS 组卒中发生率较历史组降低 44%,泵更换频率降低 40%。
  • 92% 的 PSS 组患者以比伐卢定作为主要抗凝治疗。

核心结论

  • EXCOR 上市后监测数据通过 ACTION 注册收集,显示患者结局较历史队列改善,可能源于诊疗实践变化和协作学习。

研究设计与样本

  • ACTION 为全球 40 余个儿童心衰项目的学习协作网络,收集所有 VAD 植入数据。
  • EXCOR PSS 组纳入 2018–2020 年北美 ACTION 注册中 72 例达到结局的 EXCOR 植入患者。
  • 历史对照为既往报告的 Berlin Heart EXCOR 研究组(BHS 组,n=320,2007–2014)。

主要发现

  • PSS 组较 BHS 组更年轻、体重/体表面积更小、先心病比例更高、双心室辅助比例更低。
  • PSS 组 INTERMACS Profile 1 比例更低,支持时间更长。
  • PSS 组 92% 患者主要抗凝治疗为比伐卢定。
  • 180 天成功(移植、撤除恢复或带装置存活)率 PSS 组 86%,BHS 组 76%。
  • PSS 组较 BHS 组卒中发生率降低 44%,泵更换频率降低 40%,包括大出血在内的其他不良事件均减少。

关键数值与推荐

  • 成功定义为植入后 180 天时移植、撤除恢复或带装置存活。
  • PSS 组 180 天成功率为 86%,BHS 组为 76%。
  • PSS 组卒中发生率较 BHS 组降低 44%,泵更换频率降低 40%。

临床怎么用

  • 儿童 EXCOR 支持可参考 ACTION 注册中比伐卢定为主的抗凝策略及协作学习模式改善结局。
  • 需注意 PSS 组患者特征与历史组不同,解读结局改善时应考虑病例构成差异。

局限性

  • PSS 组与 BHS 组为历史对照,非随机比较,患者特征存在差异。
  • PSS 组样本量较小(n=72),结论需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Berlin Heart EXCOR Pediatric (EXCOR) ventricular assist device (VAD) was introduced in North America nearly 2 decades ago. The EXCOR was approved under Humanitarian Device Exemption status in 2011 and received post-market approval (PMA) in 2017 from Food and Drug Administration. Since the initial approval, the field of pediatric mechanical circulatory support has changed, specifically with regard to available devices, anticoagulation strategies, and the types of patients supported. This report summarizes the outcomes of patients supported with EXCOR from the Advanced Cardiac Therapies Improving Outcomes Network (ACTION) registry. These data were part of the PMA surveillance study (PSS) required by the Food and Drug Administration. METHODS: ACTION is a learning collaborative of over 40 pediatric heart failure programs worldwide, which collects data for all VAD implantations as one of its initiatives. All patients in North America with EXCOR implants reported to ACTION from 2018 to 2020 (n = 72) who had met an outcome were included in the EXCOR PSS group. This was compared with a historical, previously reported Berlin Heart EXCOR study group (Berlin Heart study [BHS] group, n = 320, 2007‒2014). RESULTS: Patients in the PSS group were younger, were smaller in weight/body surface area, were more likely to have congenital heart disease, and were less likely to receive a bi-VAD than those in the BHS group. Patients in the PSS group were less likely to be in Interagency Registry for Mechanically Assisted Circulatory Support Profile 1 and were supported for a longer duration. The primary anticoagulation therapy for 92% of patients in the PSS group was bivalirudin. Success, defined as being transplanted, being weaned for recovery, or being alive on a device at 180 days after implantation, was 86% in the PSS group compared with 76% in the BHS group. Incidence of stroke was reduced by 44% and the frequency of pump exchange by 40% in the PSS group compared with those in the BHS group. Similarly, all other adverse events, including major bleeding, were reduced in the PSS group. CONCLUSIONS: The PSS data, collected through ACTION, highlight the improvement in outcomes for patients supported with EXCOR compared with the outcomes in a historical cohort. These findings may be the result of changes in patient care practices over time and collaborative learning.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Zafar F, Conway J, Bleiweis MS, et al. Berlin Heart EXCOR and ACTION post-approval surveillance study report. J Heart Lung Transplant. 2021. PMID: 33579597. doi:10.1016/j.healun.2021.01.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。